Blood Test Detects Hidden Ovarian Cancer Cells After Treatment

Ovarian cancer remains one of the deadliest cancers affecting women, largely because microscopic cancer cells often survive initial treatment and cause recurrence. Traditional monitoring relies on scans and blood markers that miss these tiny remnants until tumors regrow substantially.

Researchers analyzed 11 studies involving 627 ovarian cancer patients to evaluate circulating tumor DNA testing for detecting minimal residual disease. This blood test identifies DNA fragments shed by surviving cancer cells into the bloodstream.

Patients with detectable ctDNA after surgery showed 3.83 times higher progression risk and 2.84 times higher death risk compared to ctDNA-negative patients. Post-chemotherapy ctDNA detection proved even more predictive, with nearly 5-fold increased risks for both progression and death.

This breakthrough offers transformative potential for cancer survivorship and longevity. Early detection of microscopic disease could enable prompt treatment adjustments, potentially preventing full recurrence. The test provides real-time tumor monitoring without invasive procedures, supporting personalized surveillance strategies.

However, this analysis combined data from multiple smaller studies with varying methodologies. The technology requires further validation in larger, standardized trials before widespread clinical adoption. Additionally, optimal timing and frequency for ctDNA testing remain unclear, and the approach needs cost-effectiveness evaluation for healthcare systems.